Search
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Prifinium
go.drugbank.com/drugs/DB13254ExperimentalPrifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome [A175027].
Pascolizumab
go.drugbank.com/drugs/DB06560InvestigationalPascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337ApprovedBNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19. It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2. The 2025-2026 fo...
Aliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigationalAliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacio...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigational[L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated
N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide
go.drugbank.com/drugs/DB03456ExperimentalThese are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom. It is known to target cathepsin K.
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone
go.drugbank.com/drugs/DB15235InvestigationalDi-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced
Synonyms: Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazoneMolybdenum cofactor
go.drugbank.com/drugs/DB02137ExperimentalAbsence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Elunonavir
go.drugbank.com/drugs/DB21518ExperimentalElunonavir has a monoisotopic molecular weight of 1155.44 Da.